ORCID Profile
0000-0001-5596-2109
Current Organisations
St George Hospital
,
UNSW Sydney
,
Premier Specialists
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Elsevier BV
Date: 03-2022
Publisher: Oxford University Press (OUP)
Date: 02-01-2022
DOI: 10.1111/CED.15059
Abstract: Chronic bullous dermatosis of childhood (CBDC) is a rare autoimmune subepidermal blistering disease, which can develop following vaccination or medication, or with an autoimmune condition or illness, among other causes. To identify and better understand the clinical features of CBDC by performing a systematic review, in line with the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. Eligible studies included publication since 1980, CBDC diagnosis, case studies, subjects aged < 18 years, clinical features and no language restriction. A database search was conducted including Embase, MEDLINE and Scopus on 14 July 2021 (see Appendix for search terms). Data were assessed for risk of bias. Jamovi was used for statistical analysis. Age and sex were compared with mucocutaneous involvement, cutaneous involvement, other symptoms, human leucocyte antigen type and lesion descriptions. After removing duplicate references using Endnote, 351 papers were identified, of which 91 met the inclusion criteria. These papers included 130 cases of CBDC: 110 children and 20 neonates. The ratio of male : female patients was 19 : 1 for neonates and 74:55 for children. χ² analysis with 1 degree of freedom showed that CBDC in neonates was associated with facial (χ² Neonates with CBDC are more likely to have a mucocutaneous distribution of lesions, whereas children are more likely to have cutaneous lesions. The limitations of this study include selection bias, and the small neonate s le size makes the study unrepresentative of the population. The review highlights the need for further research into the clinical features of CBDC in neonates.
Publisher: Wiley
Date: 28-07-2022
DOI: 10.1111/JDV.18451
Publisher: S. Karger AG
Date: 2023
DOI: 10.1159/000529487
Abstract: Disease severity assessment tools play a large part in evaluating skin conditions in dermatology. Currently, there is no existing validated assessment tool for keratosis pilaris (KP), a benign yet highly prevalent follicular disorder. A range of proposed scoring tools have been used in different clinical trials for the assessment of potential treatments for KP. A literature review of the current scoring systems used for KP shows that there is a lack of consistency with most studies using varying versions of unvalidated investigator global assessment (IGA) scores and quartile grading systems. A review of these studies shows that current methods of evaluating KP in clinical trials are subjective, unreliable, and inconsistent. A standardised and validated scoring system would be significant as it could be used in clinical trials to advance the current knowledge of KP.
Publisher: Mucosa
Date: 31-01-2023
Abstract: Exfoliative cheilitis is an inflammatory condition that can significantly impair quality of life. This is the first reported case of an interleukin-23 inhibitor, tildrakizumab, for the treatment of a chronic, refractory case of exfoliative cheilitis.
Publisher: Oxford University Press (OUP)
Date: 12-07-2023
DOI: 10.1093/CED/LLAD215
Abstract: Our case series findings indicate that tildrakizumab treatment in patients with hidradenitis suppurativa who previously received adalimumab demonstrated an initial improvement in disease activity within the first 6 months. However, this overall trend was not sustained beyond the 6-month mark. Nevertheless, it is noteworthy that patients who underwent long-term follow-up on tildrakizumab experienced ongoing disease activity but showed a reduction in Dermatology Life Quality Index scores.
Publisher: Medknow
Date: 2023
Publisher: JMIR Publications Inc.
Date: 30-06-2023
Abstract: pidermolysis bullosa is a global orphan genetic disease. EB treatments such as expensive dressings are often unavailable in resource poor environments. o identify treatments that can be used in resource poor areas to prolong life and improve the quality of life in EB. e searched Embase, Scopus and Cochrane between 2000 and 19th June 2023 to identify epidermolysis bullosa treatments. umerous treatments range from keeping wounds clean to newer gene therapies. here is anecdotal evidence that repurposed anti-inflammatory medications can be used in the management of EB in resource poor settings.
Publisher: Wiley
Date: 13-11-2022
DOI: 10.1111/PDE.15181
Abstract: Median canaliform nail dystrophy (MCD) is a rare nail abnormality with an unknown etiology. We report the case of MCD of both great toenails in a 2-year-old boy presenting with a fir tree nail pattern and longitudinal splits. MCD was treated with topical marigold therapy (Tagetes sp.). By 15 weeks, the proximal 50% of the MCD had normalized. The report highlights a potential new treatment of marigold therapy for MCD.
Publisher: Elsevier BV
Date: 12-2022
Publisher: Wiley
Date: 16-05-2022
DOI: 10.1111/AJD.13864
Publisher: Wiley
Date: 09-04-2022
DOI: 10.1111/AJD.13830
Abstract: To describe the incidence of primary cutaneous squamous cell carcinoma in coastal NSW Australia. The design is a case-controlled study of reported cSCC from 2016 to 2019 within a defined region of coastal southern NSW. Participants include all reported pathological diagnoses of cSCC in patients greater than 20 years of age. The main outcome measures the incidence and relative risk of cSCC. The age-adjusted incidence rate of primary cSCC was 856/10 The rates of cSCC are far higher than previously reported and demand a reappraisal of our national management of this disease.
Publisher: Oxford University Press (OUP)
Date: 08-2022
DOI: 10.1111/CED.15174
Abstract: Psoriasis is a chronic inflammatory skin disease with complex comorbidities. Recent evidence has revealed how the inflammatory nature of psoriasis affects bone mineral density and may lead to osteoporosis. This review outlines the current understanding and advances on the association between psoriasis and osteoporosis. The current literature suggests an increased risk of osteopenia and osteoporosis in patients with extensive and chronic psoriasis, compounded by other lifestyle and genetic factors. It suggests that prophylactic measures such as vitamin D supplementation and increasing weight-bearing exercises can help, but in patients with extensive psoriasis, prolonged systemic inflammation may require long-term management. Although there have been many short-term RCTs on the efficacy and safety of biologics in psoriasis, clinical studies looking at the long-term effects of biologics, such as whether they might improve bone mineral density in these patients with psoriasis are yet to be conducted.
No related grants have been discovered for Anna Wilson.